HC Wainwright Estimates Sutro Biopharma Q1 Earnings

Sutro Biopharma, Inc. (NASDAQ:STRO – Free Report) – Analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for shares of Sutro Biopharma in a research note issued to investors on Friday, November 13th. HC Wainwright analyst A. Maldonado expects that the company will earn ($1.97) per share for the quarter. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Sutro Biopharma’s current full-year earnings is ($8.08) per share. HC Wainwright also issued estimates for Sutro Biopharma’s Q2 2027 earnings at ($2.18) EPS.

Sutro Biopharma (NASDAQ:STRO – Get Free Report) last posted its earnings results on Thursday, November 12th. The company reported ($1.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.64) by ($0.26). The company had revenue of $9.10 million for the quarter, compared to analysts’ expectations of $14.11 million.

Other research analysts also recently issued research reports about the stock. Citigroup reissued a “market outperform” rating on shares of Sutro Biopharma in a research report on Thursday, August 13th. Wedbush reaffirmed an “outperform” rating and issued a $60.00 price target on shares of Sutro Biopharma in a research report on Thursday, October 15th. Weiss Ratings raised Sutro Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, November 4th. Citizens Jmp cut their price target on shares of Sutro Biopharma from $41.00 to $34.00 and set a “market outperform” rating on the stock in a report on Thursday, August 13th. Finally, Stifel Nicolaus set a $48.00 price objective on shares of Sutro Biopharma and gave the company a “buy” rating in a report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Sutro Biopharma has a consensus rating of “Buy” and a consensus target price of $49.60.

Check Out Our Latest Stock Analysis on STRO

Sutro Biopharma Price Performance

Shares of STRO opened at $8.92 on Monday. The firm has a market capitalization of $148.07 million, a price-to-earnings ratio of -0.75 and a beta of 1.56. Sutro Biopharma has a 1-year low of $7.15 and a 1-year high of $43.85. The company has a 50-day moving average of $12.76 and a 200 day moving average of $22.48.

Hedge Funds Weigh In On Sutro Biopharma

Institutional investors and hedge funds have recently bought and sold shares of the business. Affinity Asset Advisors LLC grew its holdings in shares of Sutro Biopharma by 42.9% in the first quarter. Affinity Asset Advisors LLC now owns 1,069,519 shares of the company’s stock valued at $26,642,000 after purchasing an additional 321,137 shares during the period. Orbimed Advisors LLC acquired a new stake in Sutro Biopharma during the first quarter worth about $19,956,000. Perceptive Advisors LLC purchased a new position in Sutro Biopharma during the first quarter worth about $17,818,000. ADAR1 Capital Management LLC raised its stake in Sutro Biopharma by 681.8% during the first quarter. ADAR1 Capital Management LLC now owns 524,441 shares of the company’s stock worth $13,064,000 after purchasing an additional 457,364 shares during the period. Finally, Merck & Co. Inc. purchased a new position in Sutro Biopharma during the second quarter worth about $9,042,053. 96.99% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Sutro Biopharma

Investors following STRO have been watching these headlines:

  • Positive Sentiment: HC Wainwright raised its price target for Sutro Biopharma to $57, a bullish analyst signal, while maintaining its Buy rating. Sutro Biopharma Price Target Raised to $57.00
  • Positive Sentiment: HC Wainwright improved its Q4 2026 EPS estimate to a loss of $1.93 per share from a projected loss of $2.46, suggesting a less severe near-term loss outlook.
  • Negative Sentiment: The firm cut its full-year EPS forecasts substantially: to losses of $9.24 for 2027, $10.87 for 2028, $7.59 for 2029, and $7.83 for 2030. These deeper projected losses could weigh on sentiment, even though HC Wainwright retained its Buy rating.

Sutro Biopharma Company Profile

(Get Free Report)

Sutro Biopharma is a biotechnology company focused on discovering and developing targeted cancer treatments. Its research has centered on antibody-drug conjugates (ADCs), which use antibodies to deliver cancer-fighting drugs to selected cells. The company developed its XpressCF+ platform, a cell-free protein synthesis and site-specific conjugation technology intended to support the design and production of biologic medicines. Sutro’s clinical-stage programs have included luveltamab tazevibulin, an ADC targeting folate receptor alpha, and STRO-003, an ADC targeting ROR1.

Recommended Stories

Earnings History and Estimates for Sutro Biopharma (NASDAQ:STRO)

Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.